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 Abstract
Perioperative hypersensitivity reactions constitute a first-line problem for anesthesiologists and allergists. Therefore, hospitals should 
have a consensus protocol for the diagnosis and management of these reactions. However, this kind of protocol is not present in many 
hospitals, leading to problems with treatment, reporting of incidents, and subsequent etiological diagnosis. In this document, we present 
a systematic review of the available scientific evidence and provide general guidelines for the management of acute episodes and for 
referral of patients with perioperative hypersensitivity reactions to allergy units. Members of the Drug Allergy Committee of the Spanish 
Society of Allergy and Clinical Immunology (SEAIC) have created this document in collaboration with members of the Spanish Anesthesia 
Society (SEDAR). A practical algorithm is proposed for the etiologic diagnosis, and recommendations are provided for the management 
of hypersensitive patients.
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 Resumen
Las reacciones de hipersensibilidad perioperatorias constituyen un problema de primera línea para los anestesiólogos y alergólogos, por 
lo que es recomendable que los hospitales tengan un protocolo de consenso para el diagnóstico y el tratamiento de estas reacciones. Sin 
embargo, este tipo de protocolos no está presente en muchos hospitales, lo que conlleva problemas en el tratamiento, la comunicación 
de incidentes y el posterior diagnóstico etiológico. Este documento ha sido creado por miembros del Comité de Alergia a Medicamentos 
de la Sociedad Española de Alergia e Inmunología Clínica (SEAIC) en colaboración con miembros de la Sociedad Española de Anestesia 
(SEDAR). Se ha realizado una revisión sistemática de la evidencia científica disponible y se proporcionan pautas generales para el manejo 
de episodios agudos y para la derivación de pacientes con reacciones de hipersensibilidad perioperatoria a los Servicios de Alergología. Se 
propone un algoritmo práctico para el diagnóstico etiológico y se brindan recomendaciones para el manejo de pacientes con reacciones 
alérgicas perioperatorias.
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1. Introduction
During the perioperative period, patients are exposed to 
multiple agents that can induce hypersensitivity reactions, 
with an estimated incidence of 1 per 10 000 anesthesia 
procedures [1,2,3]. However, prospective studies suggest that 
this is an underestimate and quote incidences of 1:3180 [4] and 
1:1480 [5]. In a recent prospective Spanish study, the incidence 
of perioperative reactions was 1:381; of these, 48% were mild, 
involving only the skin, and 52% were anaphylaxis [6]. 
Owing to its low incidence, perioperative anaphylaxis is 
an unexpected and severe event. This hampers identification 
and early treatment and partially explains its high mortality 
(3-10% of cases) [1,7]. Perioperative hypersensitivity reactions 
constitute a first-line problem for anesthesiologists and 
allergists, and although it is advisable for hospitals to have a 
consensus protocol of action for diagnosis and treatment of these 
reactions [8], few actually do [9-12,13] and no protocols are 
specifically applicable to the Spanish population. Furthermore, 
there are no protocols of action for patients with a prior history 
of perioperative hypersensitivity reactions; these patients must 
be identified in pre-anesthesia consultations and referred to an 
allergy specialist for evaluation. This lack of specific protocols 
can imply a greater potential risk of re-exposure.
The management of perioperative hypersensitivity 
reactions is extremely complex and should be a combined 
effort between allergists and anesthesiologists [14,15] based 
on 2 well-differentiated areas [16,17]: (i) the acute phase of the 
reaction, which is the anesthesiologist’s responsibility [14]; (ii) 
later diagnosis to confirm the causal agent (if possible) which is 
the allergist’s responsibility. The aim of the present study was 
to develop clinical guidelines for the management of patients 
with a hypersensitivity reaction during the perioperative period 
and for the subsequent allergological diagnosis.
2. Methodology
A literature search was performed using key words 
agreed on by the authors. The search was performed using 
electronic databases (MEDLINE and PubMed), electronic 
libraries (Science Direct, OVID), and a database of systematic 
reviews (Cochrane Library). Publications were selected from 
between January 1985 and March 2016. The selection took into 
account the prevalence, pathogenesis, clinical manifestations, 
diagnosis, and treatment of perioperative hypersensitivity. The 
key terms used were perioperative anaphylaxis, perianesthetic 
anaphylaxis, and perioperative hypersensitivity reactions. 
In addition, the names of drugs commonly involved in 
perioperative reactions were searched for in combination 
with the terms skin tests, prick test, intradermal test, in vitro 
tests, and drug provocation tests. This search revealed 323 
publications. Original research articles and systematic reviews 
were included; nonsystematic reviews, comments, and other 
types of article were excluded. We also included studies 
examining incidence, prevalence, natural history, clinical 
manifestations, pathogenesis, diagnosis, and treatment. Studies 
not addressing perianesthetic/perioperative hypersensitivity 
were excluded. Following this review process by the expert 
panel, 195 publications were finally selected. Moreover, 
the expert panel evaluated the quality of the evidence and 
provided grades of recommendation according to the Scottish 
Intercollegiate Guidelines Network [18]. Wherever evidence 
was lacking, a consensus was reached among the experts.
3. Mechanisms of Perioperative 
Hypersensitivity
Although clinical presentation and early management are 
similar, perioperative hypersensitivity reactions may depend on 
2 mechanisms: immunological mechanisms (allergic reactions) 
and nonimmunological mechanisms [19]. IgE-mediated 
immunological reactions represent 60% of all reactions and 
their severity can increase in a subsequent surgery [20-23]. 
These reactions undergo a sensitization phase, with activation 
of TH2 and B lymphocytes and production of specific IgE 
antibodies that bind to high-affinity receptors of mast cells and 
basophils. In a second contact with the sensitizing agent and its 
binding to specific IgE, mediators such as histamine, tryptase, 
PG2, leukotrienes, thromboxane A2, platelet activating factor, 
chemokines, and cytokines such as tumor necrosis factor are 
released, leading to the development of the reaction [24]. It 
should be noted that in some cases, a reaction can occur upon 
first contact, which could be due to cross-reactivity with other 
substances to which the patient is sensitized. On rare occasions, 
immunological reactions may not be IgE-mediated, as reported 
for dextrans, which create immunocomplexes with IgG and 
activate the complement system; in such cases, these reactions 
are less severe [25]. 
Although the mechanisms are not well established, it 
is accepted that nonimmunological reactions are caused by 
direct stimulation (pharmacological or toxic) of mast cells and 
basophils, which induces their degranulation [26]; therefore, 
previous contact with the causative agent is not required [20]. 
These reactions are generally milder than immunologically 
mediated ones [7], except for a subgroup of patients, who are 
over-responders to the histamine released by neuromuscular 
blocking agents (NMBAs) [3,27,28].
4. Clinical Symptoms
The clinical manifestation of anaphylaxis due to 
anesthesia is similar to that of other forms of anaphylaxis, 
although it does present specific aspects [16,29]. Given that 
the patient is generally unconscious and covered by surgical 
drapes and cannot express what is happening, the prodromal 
symptoms (pruritus, dyspnea, or discomfort) may not be 
recognized. Instead, the reaction is often first recognized 
by the anesthesiologist, who notices nonspecific symptoms 
such as a drop in blood pressure and arterial saturation, 
difficulty in mechanical ventilation, severe arrhythmias, and 
cardiovascular collapse [1,30,31]. Consequently, some mild 
cases may recover spontaneously, meaning that the reaction 
goes unnoticed. Subsequently, re-exposure can lead to a more 
severe, potentially life-threatening reaction [4]. 
Reactions can occur at any time during anesthesia [32], 
although around 90% have been shown to occur suddenly 
during the induction phase after intravenous administration 
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of the culprit agent (especially antibiotics, NMBAs, and 
hypnotic drugs) [32]. Sometimes, reactions can occur with a 
more delayed latency period, depending on several factors: 
(i) specific agents, such as dyes [33] and colloids; (ii) route 
of administration (cutaneous, mucosal, intraperitoneal, or 
subcutaneous), which delay absorption [34,35] of agents such 
as latex [9], chlorhexidine, or surgical glues [9,10,36]; (iii) some 
surgical procedures, such as gynecological procedures, owing 
to the release of latex particles in utero after the injection of 
oxytocin [31], and some orthopedic procedures, after the release 
of the tourniquet used in surgeries with ischemia [37].
Considering the organs involved, cutaneous symptoms, 
such as erythema, urticaria, and angioedema, are observed in 
66%-70% of IgE-mediated reactions and in more than 90% of 
non–IgE-mediated reactions [38], with up to 10%-20% of cases 
not having any cutaneous symptoms [39,40]. Cardiovascular 
symptoms often include hypotension and tachycardia, which 
may progress rapidly to severe arrhythmia and cardiovascular 
collapse if they are not treated immediately [31,41-43]. 
These are the most frequent signs of severe anaphylaxis, 
and cardiovascular collapse or cardiorespiratory arrest may 
be the initial presentation symptoms [40,44]. In some cases, 
bradycardia might be the first sign of anaphylaxis; this is 
problematic, because the reaction could be confused with 
other, nonallergic anesthesia-related effects, especially if the 
patient is being treated with β-blockers. Other rare symptoms 
include acute coronary events associated with an immediate 
hypersensitivity reaction, such as Kounis syndrome, which 
is caused by the release of mediators from the cardiac mast 
cells [45,46]. Respiratory symptoms such as bronchospasm 
are less frequent and are observed in only around half of 
all patients [47], particularly those with a prior diagnosis of 
asthma [47]. The first sign may be an increase in pulmonary 
resistance or a decrease in oxygen saturation [48]. Other 
symptoms, such as alteration of coagulation [49], pulmonary 
edema, and rhabdomyolysis are very rare and are usually related 
to severe and prolonged anaphylactic shock. These symptoms 
are usually associated with the coexistence of cardiac disease, 
β-blockers, or angiotensin-converting enzyme inhibitors (ACE 
inhibitors). Given that many clinical symptoms of anaphylaxis 
reactions can be unspecific and may resemble the symptoms 
of other problems that can occur during anesthesia [9], it is 
critical to perform a differential diagnosis (Table 1).
The factors that have been identified as the main 
contributors to the clinical severity of anaphylaxis [11,40] 
include the following: (i) age, which is related to lower 
pulmonary capacity; (ii) prior diseases, especially cardiac or 
respiratory disease; (iii) systemic mastocytosis or elevated 
baseline tryptase [50]; (iv) current treatment, which may 
alter the patient’s response to catecholamine treatment, 
thereby potentially increasing mortality for medicines such as 
β-blockers, ACE inhibitors, angiotensin II receptor antagonists, 
monoaminoxidase inhibitors, tricyclic antidepressants, and 
serotonin uptake inhibitors; (v) form of administration, with the 
reaction occurring more rapidly when the drug is administered 
intravenously; (vi) initial presentation of the reaction (such 
as vascular collapse or cardiorespiratory arrest); (vii) speed 
of the clinical course (the faster the evolution, the more 
severe the reaction and the higher the risk of a fatal outcome); 
(viii) delay in administering epinephrine in the case of severe 
anaphylaxis [51,52].  
Several classification systems have been proposed to evaluate 
the severity of reactions occurring during anesthesia [11].
5. Immediate Management of 
Perioperative Reactions
The anesthesiologist has a major role to play in both the 
prevention and the treatment of hypersensitivity reactions. 
5.1. Preventive Measures 
Prior to surgery, the anesthesiologist should evaluate 
the clinical history to identify previous history of allergy 
(especially allergy relating to medicines and latex), previous 
reactions during surgical procedures, and concomitant 
diseases and their treatments. Any of these factors can affect 
the development of an allergic reaction during anesthesia and 
will influence the effect of anesthesia on patient management. 
If there is suspicion of latex allergy, the patient must be 
referred to an allergist for an allergology study prior to surgery. 
In the case of emergency surgery for a patient with suspected 
latex allergy, surgery must be performed in a latex-free 
environment. Similarly, in patients treated for a suspected drug 
allergy in the emergency department, the suspect drugs should 
Table 1. Differential Diagnosis of Perioperative Anaphylaxis 
Pharmacological effect of anesthetic agents Hypotension, bradycardia
Effect of local anesthetics or nerve block Sympathetic blockade, overdosage, accidental intravascular administration
Effect of the surgical technique Laparoscopy, eye surgery
Effect of airway manipulation  Laryngospasm, bronchospasm
Complications of surgery  Pulmonary: Pulmonary edema, pulmonary embolism, amniotic fluid, fat or air  
 embolism, pneumothorax  
 Cardiovascular: acute coronary syndrome, tachyarrhythmia, cardiac tamponade  
 Shock: hemorrhagic, septic, bone cement syndrome
Underlying disease Systemic mastocytosis, hereditary angioedema, malignant hyperthermia,  
 neuroleptic malignant syndrome, serotonin syndrome, carcinoid, or  
 pheochromocytoma
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be avoided. Locoregional anesthesia is preferred in these 
cases. Premedication with corticosteroids and antihistamines 
should be considered, especially if there is a suspicion of a 
non–immune-mediated reaction.  
5.2. Management of Reactions
In the event of a reaction, a step-by-step process must be 
followed:
5.2.1. Recognizing the allergic reaction
The anesthesiologist must evaluate the patient’s signs 
and decide whether they are indicative of anaphylaxis by 
performing a differential diagnosis (Table 1), establishing the 
severity of the reaction, and identifying possible culprit agents.
5.2.2. Treatment of the reaction 
The reaction must be treated immediately, since this will 
influence the patient’s prognosis, especially in severe reactions. 
Treatment will include general and specific pharmacological 
treatment depending on the severity of the reaction (Figure 1). 
The agents used in the treatment of the reaction can be 
classified as first- and second-line treatments: 
(a) First-line treatment 
Epinephrine. Anaphylactic reactions involve alterations 
of vascular permeability, which implies that up to 35%-50% 
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Figure 1. Treatment of perioperative anaphylaxis. ABC indicates airway, breathing, circulation; PACU, postanesthesia care unit; ICU, intensive care unit.
Second line treatment if:
1. No response to adrenaline: 
 a. Noradrenaline:  0.05-0.1 µg/kg/min
 b. Glucagon 1-2 mg iv each 5 min or perfusion 5-15 µg/min
 c. Vasopressin bolus 2-10 IU, repeat or perfusion 0.2-0.4 IU/min
2. Bronchospasm not responding to adrenaline or as a unique symptoms: Salbutamol
3. Bradycardia after cardiopulmonary resuscitation: Atropine
1. Stop administration of suspected agent
2. Maintain airway O2 and FO2 at 100%
3. Begin ABC resuscitation
4. Ask for qualified help
5. Communication with the surgeon: Decision making
Dexchlorpheniramine 5 mg
Follow the progress of the reactions
Medical discharge after clinical 
resolution
Anesthesiologist report, complete list of drugs to avoid
Study in allergology unit within 4-6 weeks following discharge






Specific management depending 
on the severity of the reaction
Patient stabilized
Obtain biological samples: Tryptase 
 IV Adrenaline bolus 20-30 µg
Fluidotherapy
Monitoring in PACU




Adrenaline IV bolus 100-200 µg
Fluid therapy
Resuscitation/monitoring in PACU
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of intravascular volume can migrate to the interstitial space 
in 10 minutes. Epinephrine is the drug of choice for treatment 
of anaphylaxis, and delay in its administration negatively 
influences the prognosis of severe reactions. There is no 
contraindication for the use of epinephrine during a reaction, 
although dosage should be adjusted based on severity in order 
to avoid severe adverse effects, especially in patients with 
heart disease. 
Vasoactive drugs. In cases where the patient is taking 
β-blockers or has heart disease, other vasoactive agents 
can be given. Norepinephrine, ephedrine, methoxamine, 
phenylephrine, and dopamine can be administered as an 
intravenous bolus or continuous infusion [53]. 
Glucagon. This drug can be also used as a rescue 
medication in patients who normally receive treatments with 
β-blockers and who may not respond to epinephrine. As with 
norepinephrine vasoactive drugs, patients with heart disease 
are advised not to take epinephrine [40,54]. 
Vasopressin. The use of vasopressin in anaphylactic shock 
is accepted, since it may be consumed during the reaction and 
no response to vasopressor drugs is observed.
Methylene blue. This drug can be useful owing to its 
capacity to interfere with the action of nitric oxide in the 
smooth muscle of vascular walls. It should be administered 
in combination with epinephrine [55-57].
(b) Second-line treatment
Antihistamines and corticosteroids. These drugs should 
not replace first-line drugs such as epinephrine for severe 
reactions, although they can be used in mild reactions 
(grade I). Corticosteroids are not indicated in the acute phase 
of the reaction, but may be used to avoid delayed symptoms. 
Systematic reviews suggest that corticosteroids are not useful 
for the treatment of anaphylaxis [57,58].
Salbutamol. Salbutamol is indicated in patients who present 
bronchospasm as a main symptom or if this symptom does not 
respond to epinephrine.
Atropine. Atropine is restricted to cases of severe 
bradycardia refractory to epinephrine and/or fluid therapy and 
in patients treated with β-blockers, as they can induce cardiac 
arrest in the early phases of anaphylaxis. 
Other treatments. Sugammadex has been proposed 
as a useful treatment for anaphylaxis symptoms caused 
by rocuronium [59,60]. However, in a recently published 
case series, sugammadex did not modify the course of the 
reaction [61]. Magnesium sulphate may be useful in cases 
of bronchospasm that are refractory to other treatments [62]. 
5.2.3. Actions after treatment 
– Obtaining biological samples for diagnosis. Blood 
should be taken during this stage in order to measure 
serum tryptase, an indicator of mast cell/basophil 
degranulation [63]. Other markers such as histamine 
and methyl-histamine in urine have been used, although 
these are not recommended in routine practice owing to 
difficulties in measurement and low sensitivity [64]. 
– Discharge. In the case of mild reactions (grade I), the 
patient can be discharged after symptoms resolve. In 
severe reactions, the patient should be observed for at 
least 24 hours in a postsurgical recovery unit, in the 
intensive care unit, or in a regular hospitalization area. 
Extreme caution must be taken with patients who present 
severe symptoms and/or do not respond to treatment and/
or experience involvement and/or severe comorbidities, 
or who have poor access to emergency treatment after 
discharge. 
– Informing the patient. Before the patient is discharged, 
the anesthesiologist should give him/her a clinical report 
containing all relevant information about the reaction, 
including its severity, any treatment administered, and 
possible causative agents. The patient should be warned 
that, if anesthesia is needed again prior to the allergology 
work-up, it should only be for emergency procedures. In 
addition, the patient must inform the hospital and present 
the clinical report. 
– Referral for allergy evaluation. With respect to a future 
diagnosis, the anesthesiologist must contact the allergist 
so that all the information about the event can be properly 
recorded. 
In order to standardize the diagnosis and treatment of 
anaphylactic reactions, it is advisable to have ready-to-use kits 
in all areas of anesthesiology departments [8,15,41] including 
the following: (i) Simple anaphylaxis treatment algorithms, 
with the dosage of different drugs, route of administration, 
especially epinephrine, and rescue medication in case of 
severe/refractory anaphylaxis (Figure 1). (ii) Instructions 
to obtain biological samples from the patient, including 
laboratory orders, sample tubes, and instructions on where the 
samples must be sent (Figure 2). This is crucial for establishing 
a chronological sequence of the events leading to the reaction. 
(iii) A standardized data sheet that should be filled in after 
the reaction has been treated and sent to the relevant allergy 
department. This sheet should include details of the drugs 
administered and the temporal sequence of symptom onset. 
Any treatments administered to resolve the reaction should 
also be described (Figure 2) [15].
6. Allergy Evaluation
The diagnosis of perioperative hypersensitivity reactions 
is based on the combination of the clinical history, in vitro 
determinations performed during the acute phase of the 
reaction, and tests performed once the reaction has resolved. 
These include skin tests, in vitro tests, and, eventually, drug 
provocation testing. The diagnostic algorithm is shown in 
Figure 3.
6.1. Clinical History
The clinical history is the first step for establishing a 
diagnosis, although all the information comes from the 
anesthesiologist’s report (grade of recommendation, D) 
[9,12,65]. It is important to evaluate various aspects, as 
follows: clinical signs and symptoms of the reaction; grade 
of severity [11]; drugs administered for treating the reaction 
and the time needed to resolve the reaction; personal history 
of allergy, including atopy and allergy to other drugs; risk 
factors, such as age; underlying diseases and treatments, such 
as β-blockers and ACE inhibitors; and all possible drugs and 
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Date of surgery: ........................................
Type of surgery: ........................................
Type of anesthesia: ...................................
Time surgery started:  ...................................................................
Time reaction started:  ..................................................................




























 Tryptase  Samplea  Time Ref. No.  
      Serum
1 Initialb YES  NO
2 After 2 hours YES  NO
3 After 24 hours YES  NO
aMark with a cross as appropriate.
bBlood sampling (serum or plasma) for mast cell tryptase immediately 
after initial treatment.
Send this document to the Allergy Service with:
– Copy of the anesthesia chart
– Copy of the anesthesia notes 
– Treatment sheet in the reanimation area
Figure 2. Data collection document and instructions.
agents used during the perioperative period, alongside details 
on their temporal sequence of administration. The agents most 
frequently involved include the following: 
6.1.1. Drugs 
Antibiotics. Antibiotics are usually administered before 
the induction phase [12] and constitute the most common 
cause of perioperative anaphylaxis in Spain [5]. It would be 
useful to separate the administration of prophylactic antibiotic 
therapy and anesthetic induction in order to identify and 
treat the reaction as early as possible. ß-Lactams, especially 
cephalosporins [5], are responsible for 70% of reactions due to 
antibiotics [20], with cefazolin being the most frequent causal 
agent in Spain [66]. Vancomycin is the second most common 
antibiotic involved, although reactions are almost always due 
to a nonimmunological mechanism [67]. Quinolones are the 
third most important group, with a high incidence [68]. Finally, 
other potentially important antibiotics include gentamicin, 
metronidazole, and tobramycin, which are mainly used in 
abdominal surgery [69]. 
NMBAs. In some studies, NMBAs are the agents most 
frequently involved in reactions [20,70,71]. Diagnosis is 
complex, as reactions can sometimes appear in patients 
receiving these drugs for the first time. This could be explained 
by the existence of cross-reactivity with other substances 
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containing tertiary or quaternary ammonium groups such as 
cosmetics, foods, industrial material, and disinfectants [72]. 
Although this hypothesis has not been proven, it was recently 
shown that contact with quaternary ammonium in hairdressing 
students is associated with an increase in the incidence of IgE 
antibodies against NMBAs [22]. It was also shown that the use 
of pholcodine, which is present in some cough medicines, is 
related to an increase in the incidence of NMBA allergy, thus 
possibly explaining differences in incidence between countries, 
as the consumption of such medicines is variable [37]. 
Finally, diagnosis is complicated by the fact that all NMBAs 
are histamine-releasing drugs, especially benzylisoquinoline 
derivatives (d-tubocurarine, atracurium, and mivacurium) [26].
Sugammadex. Sugammadex is a modified gamma 
cyclodextrin that acts as a blocking agent of the aminosteroid 
NMBAs, especially rocuronium. It can induce IgE-mediated 
reactions [73-76].
Hypnotics. These include 2 groups of chemically unrelated 
drugs (barbiturates and nonbarbiturates). Drugs from the 
barbiturate group are used infrequently nowadays. Thiopental 
is the most highly consumed, and although IgE-mediated 
reactions have been reported, most are induced by nonspecific 
histamine release [77]. 
The nonbarbiturate group includes propofol, ketamine, 
etomidate, benzodiazepines, and inhaled anesthetics. Propofol 
is the cause of 2.3%-2.6% of perioperative anaphylactic 
reactions [20,78], most of which are IgE-mediated; the 
antigenic determinant is the 2-isopropyl group of the molecule 
(2,3 diisopropylphenol). Soybean oil and egg-derived lecithin 
are both used during its formulation, and although it has been 
suggested that patients with severe anaphylaxis to egg and/or 
soy should undergo an allergology work-up or use alternative 
treatment [79], these drugs seem to be safe in most patients. 
One study of 99 patients with positive specific IgE to egg, 
soya, or peanut (only 44% had immediate clinical symptoms) 
found that none had an allergic reaction following exposure 
to propofol [78]. In a Spanish study of 52 adult patients with 
eosinophilic esophagitis sensitized to egg, soy, or peanut, none 
of the patients who received propofol before an endoscopy 
procedure reacted to the drug [80]. In fact, according to 
our literature search, no reactions to propofol have been 
documented for soy- or egg-allergic patients. Moreover, prick 
testing with soya oil and propofol has always yielded negative 
results, indicating that there are no reasons to contraindicate 
its use [79,80].
Hypersensitivity reactions to benzodiazepines are 
extremely rare; midazolam was the most frequent etiological 
agent in the few cases that have been reported [7,20]. Reactions 
to etomidate and ketamine are also rare; in fact etomidate is 
considered one of the safest drugs in anesthesia in terms of 
allergic reactions [7,81]. 
Opioids. Reactions are rare, and although there have been 
some IgE-mediated reactions, most are due to nonspecific 
histamine release [82-85]. Semisynthetic opioids such as 
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Figure 3. Algorithm for diagnosing perioperative hypersensitivity reactions. NSAID indicates nonsteroidal anti-inflammatory drug.
Clinical History
History of perianesthesic  
allergic reaction








Drug provocation test Nonallergic
No data on culprit agentData on culprit agent





Skin tests with culprit 
agents+latex+chlorhexidine
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fentanyl, alfentanil, remifentanil, and sufentanil do not cause 
histamine release by themselves. Morphine derivatives are 
chemically different from phenylpiperidines, and there is 
no cross-reactivity between them [82-86]. While infrequent, 
allergic reactions to opioids are an important problem because 
these drugs are essential for anesthesia and it is difficult to find 
a safe alternative. 
Nonsteroidal anti-inflammatory drugs (NSAIDs). 
NSAIDs are responsible for a high number of perioperative 
reactions [5,20]. In general, nonimmunological reactions due 
to COX-1 inhibition are more common [29]. In some cases, 
the underlying mechanism can be immunological, most often 
due to pyrazolones, followed by diclofenac, although again, 
specific studies relating to incidence in perioperative reactions 
are needed [87].
Local anesthetics. Although widely used, local anesthetics 
rarely induce adverse effects related to overdose or accidental 
intravascular administration [88]. In exceptional cases, they 
induce hypersensitivity reactions, which are mainly associated 
with the amide group [39,89].
Other drugs. There have been anecdotal reports of cases of 
anaphylaxis induced by heparins [39], tranexamic acid [90], 
uterotonic drugs [91,92], atropine [93], and neostigmine [93].
6.1.2. High-molecular-weight agents
Colloids. These can cause up to 4% of perioperative 
anaphylactic reactions, usually appearing 20-30 minutes after 
initiation of the infusion [1]. Gelatins are responsible for most 
reactions (95%), followed by dextrans, and although both can 
induce nonspecific histamine release, IgE-mediated reactions 
due to gelatins and IgG-mediated reactions due to complement 
activation by dextran have been reported [39,94]. Gelatins can be 
a cause of anaphylaxis in patients sensitized to the carbohydrate 
epitope α-gal [95]. The incidence of reactions is much lower for 
albumin and exceptional for hydroxyethyl starch [96,97].
Protamine. Hypersensitivity reactions mediated by IgG, 
IgE, complement activation, and nonspecific histamine release 
have been reported [17,98]. Patients who have been previously 
exposed to this drug are at a higher risk of developing a 
reaction, regardless of whether the drug was given for blocking 
the effect of heparin or combined with insulin. Protamine is 
derived from fish sperm; however there is no increased risk for 
patients undergoing vasectomy or those allergic to fish [58]. 
It is important to be aware that rapid protamine infusion can 
induce hypotension.
Aprotinin. Aprotinin is a bovine-derived protease inhibitor 
used via the parenteral route as a fibrinolysis inhibitor or 
topically as a surgical glue [17]. The incidence of reactions 
in cardiac surgery is 0.5%, although this can increase to 
2.5%-2.8% in patients who have previously undergone 
multiple surgeries [99,100], especially during the previous 
6 months [31]. Perioperative anaphylaxis has also occurred 
upon the first parenteral administration in patients who had 
previously received topical aprotinin [17].
Hyaluronidase. Hyaluronidase is a bovine or ovine enzyme 
that degrades hyaluronic acid and can be used as a drug or 
fluid adjuvant. Both immediate reactions [101] and delayed 
reactions [102] have been reported during ocular surgery and 
epidural injection. 
6.1.3. Antiseptics and sterilizers
Antiseptics. There are significant geographical differences 
with respect to the incidence of chlorhexidine-induced 
perioperative anaphylaxis. Reactions have been reported 
to be frequent in the UK and Scandinavia [71,103,104], 
with chlorhexidine accounting for 8.7%-9.6% of cases of 
perioperative anaphylaxis; however, such reactions were 
found to be relatively rare in France [22], perhaps because of 
the limited use of chlorhexidine in the operating room. The 
mechanism is IgE–mediated, and although reactions usually 
appear 20-30 minutes after administration, onset and severity 
depend on the administration route, with cutaneous application 
rarely causing severe reactions [36]. Nevertheless, when it 
is applied to mucous membranes (urinary catheters or oral 
cavity washes) or by parenteral routes (venous catheters or 
surgical meshes), the onset of clinical symptoms can be faster 
and more severe [36,104,105]. The appearance of anaphylaxis 
induced by povidone is unusual, and it is noteworthy that 
no cross-reactivity with iodinated contrast media has been 
reported [12,70]. 
Sterilizers. Ethylene oxide is a gas used for sterilizing 
multiple medical devices. Reactions have mainly been 
described in dialyzed patients and in those with spina bifida 
and are extremely rare during perioperative reactions [1]. 
Administration of anesthesia without ethylene oxide is a 
challenge for the anesthesiologist, because in some cases 
it cannot be substituted. The case is similar for some intra-
arterial catheters, pump infusion systems, and intratracheal 
tubes. 
6.1.4. Dyes
Isosulfan blue, its isomer patent blue V, and methylene blue 
are used for mapping sentinel lymph nodes in patients with 
breast cancer or melanoma. They are all capable of inducing 
hypersensitivity reactions, and the incidence of such reactions 
has been on the increase in the last decade owing to a rise 
in their intraoperative use [106]. Isosulfan blue and patent 
blue V can induce anaphylaxis in up to 1% of individuals who 
receive it, with reactions usually appearing 10-30 minutes 
after administration [107]. The typical reaction involves the 
appearance of blue wheals [108], although severe reactions 
with shock can appear in some cases. In most cases, there has 
been no previous medical exposure to these dyes, and it is 
thought that sensitization occurs through exposure to cosmetics 
or other objects. Anaphylaxis induced by methylene blue is 
less frequent, and this agent can be an alternative in patients 
sensitized to isosulfan blue [107], although cross-reactivity 
has been described in a few cases [109].
6.1.1. Latex
A decrease in the number of reactions to latex has been 
reported in several countries as a result of the reduction in 
latex exposure and sensitization by decreasing the protein 
content and stopping the use of powdered gloves [110,111]. The 
absorption of latex allergens usually occurs through the skin 
and mucous membranes, and although reactions can appear at 
any time during surgery, onset of symptoms is usually delayed. 
Abdominal, gynecological, and orthopedic surgery are usually 
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associated with an increased risk, and incidence is likely to be 
higher in the case of atopic patients, health system personnel, 
workers exposed to latex, patients undergoing multiple 
surgeries, women undergoing in vitro fertilization, children 
with urogenital malformation or spina bifida, and those with 
a history of perioperative anaphylaxis [112,113]. 
6.2. Skin Tests
Skin tests are the initial diagnostic approach. Interpretation 
of the results depends on clinical symptoms (grade of 
recommendation, B). In most cases, the skin prick test will be 
followed by an intradermal test. A skin prick test is considered 
positive when the mean wheal diameter is larger than 3 mm 
and surrounded by erythema and when the saline control is 
negative [87]. An intradermal test is considered positive when 
there is an increase greater than 3 mm of the initial wheal made 
by injection of the drug [87] (grade of recommendation, C). 
Skin testing should be performed within 4-6 weeks after the 
reaction. Sensitivity decreases over time; this decrease is faster 
for ß-lactams than for NMBAs (grade of recommendation, D) 
[114,115].  
The optimal concentration for skin tests is not clearly 
defined in all cases for drugs that can induce nonspecific 
histamine release [116,117]. Therefore, false-positive 
results can occur with drugs such as NMBAs (mivacurium, 
atracurium, cisatracurium, and succinylcholine), thiopental, 
opioids, and some antibiotics such as vancomycin and 
quinolones. A detailed investigation to determine the maximal 
nonreactive concentration for NMBAs in healthy individuals 
has been performed [118]. The concentrations recommended 
as nonirritant are shown in Table 2 [31,119]. 
Skin testing with NMBAs is considered to be highly 
sensitive (>95%) and specific (96-98%) and therefore 
mandatory for diagnosis and evaluating cross-reactivity, 
although this observation needs to be confirmed in other 
populations (grade of recommendation, C) [120]. Cross-
reactivity among NMBAs has been reported, thus making 
it necessary to test other NMBAs when looking for a safe 
alternative (grade of recommendation, C) [9,12,121]. In 
addition, skin prick tests with latex show high sensitivity 
and specificity (grade of recommendation, B) (93% and 
100%, respectively) [122]. Chlorhexidine is also highly 
sensitive and specific: 95% and 97%, respectively, for skin 
prick tests and 68% to 100% for intradermal tests (grade of 
recommendation, B) [103]. 
Skin testing can also be useful for diagnosing allergic 
reactions to antibiotics. However, except for ß-lactams, 
in which sensitivity has been estimated to be 70% [123], 
sensitivity and specificity are not well established (grade of 
recommendation, B) [119]. In the case of NSAIDs, skin testing 
is only recommended for reactions to pyrazolones (grade of 
recommendation, C) [87,124]. Skin testing can be used to 
diagnose hypersensitivity reactions to hypnotic drugs [125], 
sugammadex [126], local anesthetics [89], and dyes [127] 
(grade of recommendation, C). The value of skin testing 
with opioids such as morphine for detection of perioperative 
reactions is unclear owing to their capacity to induce nonspecific 
histamine release (grade of recommendation, C) [116]. Given 
the mechanisms of reactions to dextrans (immune complex–
mediated or complement activation), the value of skin tests is 
not established (grade of recommendation, D) [12]. 
There is some controversy over when to perform skin 
tests and which agents to use. The allergist has a key role 
here. Various scenarios can occur in clinical practice. First, 
patients have no previous clinical history of perioperative 
allergic reaction. In these cases there is no indication to 
perform skin tests (grade of recommendation, B) [12,118,128]. 
Second, patients may have a previous history of reactions, with 
detailed information on reaction kinetics and drugs and agents 
administered. In these cases, skin testing is mandatory for all 
the agents administered plus latex [129] and chlorhexidine 
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Table 2. Recommended Concentrations for Skin Tests: Skin Prick Tests 
and Intradermal Tests 
  SPT Concentration  IDT Concentration
NMBAs 
 Atracurium 1 mg/mL 0.01 mg/mL 
 Cisatracurium 2 mg/mL 0.02 mg/mL 
 Mivacurium 0.2 mg/mL 0.002 mg/mL 
 Pancuronium 2 mg/mL 0.2 mg/mL 
 Rocuronium 10 mg/mL 0.05 mg/mL 
 Vecuronium 4 mg/mL 0.4 mg/mL 
 Suxamethonium 10 mg/mL 0.1 mg/mL
Hypnotics   
 Etomidate 2 mg/mL 0.2 mg/mL  
 Ketamine 10 mg/mL 1 mg/mL 
 Propofol 10 mg/mL 1 mg/mL 
 Thiopental 25 mg/mL 2.5 mg/mL 
 Midazolam 5 mg/mL 0.5 mg/mL
Opioids   
 Alfentanil 0.5 mg/mL 0.05 mg/mL 
 Fentanyl 0.05 mg/mL 0.005 mg/mL 
 Remifentanil 0.05 mg/mL 0.005 mg/mL 
 Sufentanil 0.05 mg/mL 0.0005 mg/mL 
 Morphine 1 mg/mL 0.01 mg/mL
Sugammadex Undiluted 1/100
β-lactams   
 BPO-OL 0.04 0.04 
 MD 0.5  0.5  
 Amoxicillin 20 mg/mL 20 mg/mL 
 Cephalosporins 20 mg/mL 2 mg/mL
Local anesthetics Undiluted 1/10
Heparins Undiluted 1/10
Tranexamic acid Undiluted 1/10
Protamine Undiluted 1/1000-1/10 000
Aprotinin 1/5 1/500
Hyaluronidase Undiluted 1/10
Antiseptics   
 Chlorhexidine 5 mg/mL 0.002 mg/mL
Dyes 
 Patent blue Undiluted 1/10 
 Methylene blue Undiluted 1/10
Abbreviations: BPO-OL, benzylpenicilloyl; IDT, intradermal test; MD, 
minor determinant; NMBA, neuromuscular blocking agent; SPT, skin 
prick test.
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[71,103,104,130] (grade of recommendation, C), although 
results may not be reliable until 4-6 weeks after the initial 
reaction [131]. Third, patients may have experienced reactions 
but provide no clear information on the episode—the most 
complex scenario—especially when there is a long interval 
between the reaction and the study. In this case, the type of 
surgery and anesthesia and the severity of the reaction can help 
when choosing the agents to test. Nevertheless, skin testing 
should be performed with all the essential agents needed for 
anesthesia, including a muscle relaxant derivative and an 
opioid (grade of recommendation, D) (Table 3).
6.3. In Vitro Tests
In vitro tests can be performed during the acute phase of the 
reaction or once it has subsided. The former help to understand 
the mechanisms involved in and the latter to identify the culprit 
agent (grade of recommendation, C).
6.3.1. Acute phase of the reaction 
In this case, tests are mainly based on the determination 
of histamine and tryptase.
Determination of plasma histamine. Levels of histamine 
usually increase in the first 5-10 minutes after symptom 
onset; their half-life is 15-20 minutes, which is why blood 
samples need to be taken during the first 15-30 minutes of the 
reaction [11,132]. It is important to maintain the tube at 4ºC 
until processing to avoid nonspecific release due to cellular 
lysis. This determination is not sufficiently standardized for 
diagnostic use (grade of recommendation, C). 
Determination of serum tryptase. Tryptase stays in the 
blood for hours, with maximum levels appearing after 1-2 
hours and remaining high for a further 4-6 hours. This means 
that blood samples can be obtained between 30 minutes and 
6 hours after the reaction. Moreover, the samples are less 
sensitive to environmental conditions, as determination is 
performed in serum. Various cut-offs have been considered, 
ranging from 8.23 μg/L to 11.4 μg/L [94-96], although the 
best criterion is a 2-fold or 2+1.2× increase above baseline 
levels (grade of recommendation, B) [63,133]. Tryptase 
levels are especially high in more severe reactions [134,135]. 
However, since the measurement of tryptase also accounts 
for a high frequency of false negatives and a low predictive 
value (54%), a normal tryptase value does not rule out real 
anaphylaxis [93]. Although tryptase is more often increased 
than histamine, the former suggests an IgE-mediated reaction 
[30,134]. Furthermore, tryptase can be determined in deceased 
patients [11,30,136]. 
6.3.2. Resolution phase 
In vitro methods are further described in Table 4.
Specific IgE determination. This method is useful when 
combined with skin test results, but not in isolation (grade of 
recommendation, B). The most widely available method is 
ImmunoCAP (Thermo Fisher), which can be used with latex, 
suxamethonium, morphine, pholcodine, bovine gelatine, 
protamine, chlorhexidine, thiopental, ethylene oxide, and 
some antibiotics. It is also possible to determine specific IgE 
to quaternary ammonium using the same method, and this can 
be used as a marker of sensitization to NMBAs and opioids. 
As this determination is positive in 3%-10% of nonallergic 
patients, results should be interpreted with caution [137]. 
Basophil activation test (BAT). BAT is useful when 
confirming skin test results for diagnosing or assessing cross-
reactivity [138] (grade of recommendation, B). Some authors 
have obtained promising results in reactions induced by muscle 
relaxants; consequently, the test is recommended for routine 
analysis [139]. Moreover, some authors consider that performing 
the BAT with muscle relaxants is useful for diagnosis, even in 
patients with negative skin test results, and that it can be used for 
the identification of safe alternatives [137,139,140]. However, 
identification of safe alternatives based on BAT only should be 
regarded with caution, taking into account that only small series 
with BAT have been reported. 
Other determinations. Histamine and sulphidoleukotriene 
release assays have limited utility (grade of recommendation, C) 
[141,142].
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Table 3. Agents and Drugs Panel to Use in Skin Testing in Those Patients 
Where the Possible Culprits Are not Identified by the Clinical History 










Table 4. Available In Vitro Methods for Identifying the Culprit Agent 




Local anesthetics Xa X







Ethylene Oxide  X
Abbreviation: BAT, basophil activation test.
aResearch: thiopental, mepivacaine, propofol, rocuronium, paracetamol, 
diclofenac.
bAvailable: suxamethonium.
cAvailable: pholcodine and morphine.
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6.4. Drug Provocation Tests
Drug provocation tests are considered the gold standard for 
diagnosing drug hypersensitivity (grade of recommendation,  C) 
and consist of the administration of increasing doses of the drug 
at 30 minute intervals in a single-blinded and placebo-controlled 
manner until the therapeutic dose is reached or a reaction 
occurs [143,144]. Many of the drugs administered during the 
perioperative period, such as antibiotics and NSAIDs, are studied 
following regular procedures and are beyond the scope of this 
review. However, DPT with perioperative drugs has several 
added limitations, and there is no consensus procedure (grade 
of recommendation, C) [10,145,146]. The goal is to reach a total 
dose of the drug needed for induction of anesthesia (propofol, 
etomidate, ketamine) or to be administered during the anesthetic 
procedure (opioids, midazolam). This dose is not standard for all 
patients and depends on body weight and underlying diseases 
(Table 5) [147,148].
Although some of these agents can be administered 
in allergology units, many require coordination with the 
anesthesiology unit. Cardiovascular and respiratory monitoring 
is mandatory.
– Drugs administered in the allergy unit. It is generally 
preferable to use the oral and subcutaneous routes 
(grade of recommendation, D), with close monitoring 
of the patient. Every attempt should be made to avoid 
high-risk patients such as older patients or patients 
with comorbidities; for example, drug exposure might 
provoke reactions that are hard to control [143]. Among 
the opioids, morphine, pethidine, and fentanyl can 
generally be administered without major adverse effects, 
and if they do appear, they can be reversed with naloxone 
at an initial dose of 0.4 mg and repeated every 2-3 
minutes until a response is obtained or a maximum dose 
of 10 mg is achieved [149]. Benzodiazepine is quite safe, 
and its sedative effects can be reversed with flumazenil, 
starting with a dose of 0.2 mg, and if necessary, repeating 
the dose of 0.2 mg each minute until a maximum dose 
of 1 mg is reached [149].
– Drugs administered in the surgery area. This approach 
is only indicated when there are no alternatives to 
administering anesthesia. A risk-benefit analysis should 
be performed, and administration should be intravenous 
(grade of recommendation, D) [3,10]. It should be 
performed in a setting with adequate cardiovascular 
and respiratory monitoring and in the presence of 
well-trained personnel to manage cardiovascular 
events (hypotension, bradycardia), respiratory events 
(depression), and hypersensitivity reactions (grade of 
recommendation, C). The most adequate setting is the 
operating room or the postanesthesia unit. The necessary 
material and personnel are as follows: (i) an anesthetist 
and an allergist throughout the DPT procedure and 
recovery; (ii) nurses trained in the management of 
airway and cardiovascular events; (iii) individualized 
monitoring (ECG, noninvasive blood pressure, pulse 
oximetry, and respiratory rate); (iv) resuscitation 
trolley and airway handling material; (v) a ventilator or 
anesthesia machine, especially if the DPT is performed 
with muscle relaxants or in high-risk patients (Physical 
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Table 5. Doses Administered in the Drug Provocation Test 
Drug Setting Route Maximum Dose
Opioids 
 Morphine AU Oral 5 mg; 10 mg in <65 years 
 Pethidine  SC 25 mg 
 Fentanyl  SC 50 µg
Benzodiazepines 
 Midazolam AU Oral 3.5-5 mg 
 Diazepam  Oral 5-10 mg
Opioids 
 Morphine hydrochloride PU IV 0.1 mg/kg (10 mg) 
 Meperidine  IV 0.5 mg/kg (50 mg) 
 Fentanyl  IV 1-2 µg/kg 
 Alfentanil  IV 10-20 µg/kg 
 Remifentanil  IV Continuous infusion (0.05-0.1 µg/kg/min) 
 Sufentanil  IV 0.1 µg/kg
Hypnotics 
 Propofol PU IV 1-2 mg/kg 
 Etomidate  IV 0.2-0.3 mg/kg 
 Ketamine  IV 0.5-2 mg/kg
NMBAs 
 Cisatracurium PU IV 0.5 mg/kg 
 Atracurium  IV 0.1-0.15 mg/kg 
 Rocuronium  IV 0.6 mg/kg 
 Vecuronium  IV 0.1 mg/kg
Abbreviations: AU, allergology unit; IV, intravenous; NMBA, neuromuscular blocking agent; PU, postanesthetic unit; SC, subcutaneous.
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Status Classification System of the American Society of 
Anesthesiology [ASA] 3 and 4) [150].
Extra considerations may include the following: (i) 2 signed 
informed consents, one for the allergological study and the 
other for the anesthetic procedure, specifying the risks of each 
procedure and with a previous study in the allergology and 
anesthesiology units; (ii) possibility of nonspecific histamine 
release and hypotension with certain drugs (succinylcholine, 
rocuronium, atracurium, mivacurium, morphine, and 
meperidine), which can hamper diagnosis [143,145,151]; 
(iii) the complexity of the procedure requires DPT with 
different drugs consecutively on the same day, with 1-hour 
intervals between each drug. This is possible, as drugs are 
administered intravenously and most reactions appear in less 
than 30 minutes; (iv) monitoring of the patient during the 
recovery phase after finishing the DPT.
The drugs that usually need to be tested are opioids, 
because there is no alternative and hypnotics that are essential 
for anesthetic induction, particularly propofol, are the most 
widely used agents for anesthesia and sedation [78,80,152]. 
Testing is not recommended for muscle relaxants owing to 
potential effects on breathing, with the exception of those cases 
where they are suspected of causing a reaction and where they 
are absolutely necessary to perform surgery and no alternatives 
exist [144]. Testing is indicated in specific situations where the 
anesthetist needs to know tolerance to NMBAs, for example, 
in transplant procedures, high-risk patients, or when skin 
tests are not valuable. As NBMAs cannot be used alone, it is 
recommended to test them after other drugs, such as propofol, 
to control the airway by endotracheal intubation, which will 
enable better control in case of a reaction. It is recommended 
to test a muscle relaxant other than that inducing the reaction. 
This should yield negative skin test and BAT results, and, if 
possible, be from a different chemical group, especially in the 
case of cisatracurium and rocuronium [9,146,151].
7. Recommendations After  
the Allergological Study
Once the allergological study is finished, a medical 
report must be produced with a detailed description of 
the drugs involved, the type of reaction, the allergology 
work-up results, diagnosis, and recommendations (grade of 
recommendation, D). This will be essential when deciding on 
the best anesthetic procedures for the patient in the future. The 
various possibilities are as follows:
– Patient with a clinical history that not suggestive and 
negative allergology findings. 
 If the patient has not presented a hypersensitivity drug 
reaction, the recommendation is to use any anesthetic 
procedure with the same risk as for the general population 
(grade of recommendation, D). 
– Patient with a suggestive clinical history and negative 
allergology results. 
 In this scenario, the various possibilities are as follows: 
- If the allergological study has only been based on 
the performance of skin tests accompanied or not by 
in vitro tests and a drug provocation test cannot be 
performed, then it is not possible to rule out an allergic 
reaction [109]. If the drugs involved in the reaction 
are known, the best approach is to avoid them as well 
as any others that may cause cross-reactivity (grade 
of recommendation, D). If the drugs involved are 
not known, the best approach is to use locoregional 
anesthesia (if possible) or general anesthesia, but 
without using NMBAs or drugs with a high capacity 
to induce nonspecific histamine release (grade of 
recommendation, D) [6]. Moreover, it is important 
to re-evaluate the patient by testing emerging agents 
such as chlorhexidine, methylcellulose, polyethylene 
glycol/macrogol, mannitol, dyes, and any other drugs 
not initially considered due to improbability. It is also 
important to assess any methodological problems in 
the testing procedures (failure in concentration or skin 
test reading) (grade of recommendation, D). 
- If the allergological study was based on provocation 
testing, drugs with confirmed tolerance will be 
recommended (grade of recommendation, D).
- In cases where nonspecific histamine release is 
suspected, the recommendation is to avoid drugs 
with potent histamine-releasing capacity the next 
time anesthesia is administered. Pretreatment with 
antihistamines is also recommended [11,153], and all 
drugs should be administered slowly and one by one 
[10,145] (grade of recommendation, D). 
– Patient with a suggestive clinical history and positive 
allergology results. 
 The recommendation is to avoid the agent identified 
as allergic and those with cross-reactivity. In these 
cases, pretreatment is not useful for preventing a new 
reaction [154]. The recommendations will depend on the 
culprit drug, as follows: 
- NMBAs. The recommendation is to use a muscle 
relaxant that yields negative results in intradermal 
skin tests and the BAT [12,140]. Although there is 
considerable cross-reactivity between muscle relaxants 
(65% if the reaction was induced by rocuronium and 
29% for succinylcholine) [155], sensitization to all of 
them is low (grade of recommendation, C) [146]. If this 
is the case and all NMBAs yield positive results in skin 
tests and/or BAT, one might consider a locoregional 
anesthesia or tracheal intubation after induction of 
anesthesia using inhalant agents or combinations of 
opioids and hypnotics (midazolam, propofol, fentanyl) 
plus local anesthetics such as lidocaine [154-156] 
(grade of recommendation, D). 
- Hypnotics. Since hypnotics do not present cross-
reactivity, it should be possible to replace one hypnotic 
with another. Currently, most reactions are due to 
propofol. Ketamine and etomidate provide effective 
sedation with limited effects on hemodynamic function. 
The better alternative in patients with cardiovascular 
disease is etomidate. Ketamine induces dissociative 
anesthesia with minimum respiratory depression and 
no cardiodepressant effects and is especially useful 
in hemodynamically unstable patients or critically 
ill patients. Thiopental is rarely used nowadays. In 
cases of endoscopy, a combination of midazolam and 
fentanyl has been recommended [157]. 
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- Opioids. The incidence of anaphylaxis is quite low, 
and most cases are due to nonspecific histamine 
release. In such cases, it is important to avoid 
morphine, meperidine, and codeine, all of which have 
a high capacity for stimulating mast cells in the skin. 
Recommended alternatives include phenylpiperidine 
drugs (fentanyl, alfentanil, remifentanil, sufentanil), 
which have a low histamine release capacity. In IgE-
mediated reactions induced by morphine, it seems 
useful to use remifentanil or fentanyl; morphine can 
be used in cases of reaction to fentanyl [83-86]. 
- Colloids/crystalloids. Gelatins and dextrans are the 
substances most frequently involved [158]. Cross-
reactivity between them has not been reported. 
- Latex. Every hospital should have protocols for 
operations involving patients with latex allergy. If 
there is no specific operating room, then the surgery 
should be performed early in the day and without 
materials containing latex in order to avoid the 
presence of latex particles in the environment [113]. 
Similar precautions should be taken when the patient 
is moved to the postsurgery room or any other part of 
the hospital [113].
- Local anesthetic. Reactions are quite infrequent and 
are generally not due to hypersensitivity. If confirmed, 
an alternative with confirmed tolerance can be used.
- Dyes. Reactions have been mainly reported for 
patent blue V and isosulfan blue, which cross-react. 
Methylene blue can be used as an alternative if the 
allergological study is negative [159].
- Antiseptics and sterilizers. In cases for which 
hypersensitivity to chlorhexidine or povidone-iodine 
is confirmed, they should be avoided, and other drugs 
without cross-reactivity should be used. When this is 
not possible, as with ethylene oxide, the area should 
be washed several times in physiological saline 
before use. The same procedure should be followed 
with ortho-phthalaldehyde solution, although this has 
generally been replaced by peracetic acid owing to its 
higher sensitizing capacity.
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